Impact of 1-week preoperative auto-CPAP treatment on postoperative outcomes in patients undergoing heart valve replacement surgery: a prospective randomized controlled trial

Mei Su, Wei Lin, Qi Xu, Buqing Ni, Xilong Zhang, Shijiang Zhang, Ning DingFrontiers in Neurology 2023 · DOI

This study, published in Frontiers in Neurology, explores how a brief window of "pre-habilitation" using auto-CPAP can significantly improve recovery trajectories for heart surgery patients.

TL;DR

A one-week course of preoperative auto-CPAP treatment for patients with obstructive sleep apnea (OSA) undergoing heart valve replacement significantly reduces the time spent on mechanical ventilation and shortens both ICU and postoperative hospital stays. While it didn't lower the rate of specific complications like pneumonia, it effectively accelerated the overall recovery process.

What Problem Does This Paper Address?

Obstructive Sleep Apnea (OSA) is a common but often underdiagnosed condition characterized by repeated airway collapse during sleep. For patients undergoing major surgery—specifically Cardiac Valve Replacement (CVR)—OSA is a major red flag. It is linked to increased "oxygen debt," systemic inflammation, and a higher risk of postoperative cardiovascular events.

While Continuous Positive Airway Pressure (CPAP) is the gold-standard treatment for OSA, its use in the immediate perioperative period (the time around surgery) is inconsistent. Specifically, researchers didn't know if a short, one-week "burst" of CPAP treatment before surgery could actually change the outcome for CVR patients. This paper seeks to bridge that gap with a randomized controlled trial.

Methods

The researchers conducted a prospective randomized controlled trial (RCT) involving 32 patients diagnosed with both rheumatic valvular heart disease and OSA (defined as an Apnea-Hypopnea Index or AHI ≥ 5).

  • The Intervention: Patients were split into two groups. The treatment group received one week of auto-CPAP (a device that automatically adjusts pressure between 4–16 cm H2O) plus basic medical care. The control group received only basic medical care.
  • The Surgery: All patients underwent CVR surgery one week after the treatment period ended.
  • Blinding: To maintain rigor, the statistician and data collectors were blinded to which patients received CPAP, and care providers were blinded to the specific outcome parameters being measured.
  • Standardization: All patients used the same model of CPAP device and underwent standardized surgical and ICU protocols.

Datasets

As a clinical trial, the "dataset" consists of the patient cohort:

  • Total Screened: 223 patients.
  • Final Enrolled: 32 patients (15 in the CPAP group, 17 in the non-CPAP group).
  • Criteria: Adults (18–75) with rheumatic valvular heart disease and confirmed OSA via polysomnography (PSG).
  • Exclusions: Patients with prior strokes, congenital heart disease, or chronic lung diseases like COPD/asthma were excluded to isolate the effects of OSA and CVR.

Key Insights and Ideas

  • The "Pre-hab" Advantage: The study demonstrates that even a very short duration (7 days) of preoperative CPAP can have a measurable impact on surgical recovery. This suggests that reducing the chronic "oxygen debt" and airway inflammation associated with OSA immediately before the stress of surgery pays dividends in the ICU.
  • Ventilator Weaning: The most significant finding was the reduction in mechanical ventilation time. Patients who used CPAP were able to breathe on their own sooner. This is likely because CPAP improves lung volume and gas exchange efficiency before the patient ever hits the operating table.
  • Feasibility and Compliance: One common concern with CPAP is patient adherence. However, this study reported an 88% adherence rate (>4h per night). This suggests that a short-term, goal-oriented preoperative protocol is highly acceptable to patients.

Key Results

The study found statistically significant improvements in recovery metrics for the CPAP group:

  • Mechanical Ventilation Duration: Reduced from a median of 24 hours in the control group to 17 hours in the CPAP group (p = 0.010).
  • ICU Stay: Shortened from 36 hours to 22 hours (p = 0.040).
  • Postoperative Hospital Stay: Reduced from 15 days to 12 days (p = 0.044).
  • Complications: Interestingly, there were no significant differences in the rates of cardiac arrhythmias, pneumonia, or reintubation. This suggests the primary benefit was in the speed of recovery rather than the prevention of major adverse events (though the small sample size may have limited the ability to detect these differences).

Limitations and Future Work

The authors acknowledge several limitations:

  1. Sample Size: With only 32 patients, the study may have been underpowered to detect differences in rarer complications like pneumonia or specific arrhythmias.
  2. Short-term Focus: The study only looked at in-hospital outcomes (up to 15 days post-op). Long-term recovery and quality of life were not assessed.
  3. Pre-op vs. Post-op: The study only tested preoperative CPAP. It remains unclear if continuing CPAP after surgery would provide additional synergistic benefits, or if the preoperative phase is the most critical "window of opportunity."

Future research is needed to determine the "optimal dose" of preoperative CPAP—would two weeks be better than one?—and to see if these results hold up in larger, multicenter trials.

Summary updated

Abstract

We concluded that in patients underwent CVR, preoperative use of auto-CPAP for OSA significantly decreased the duration of mechanical ventilation, and postoperative stays in the ICU and hospital.<b>Clinical Trial Registration</b>: https://ClinicalTrials.gov, identifier NCT03398733.
BibTeX
@inproceedings{su2023impact,
  author = {Mei Su and Wei Lin and Qi Xu and Buqing Ni and Xilong Zhang and Shijiang Zhang and Ning Ding},
  title = {{Impact of 1-week preoperative auto-CPAP treatment on postoperative outcomes in patients undergoing heart valve replacement surgery: a prospective randomized controlled trial}},
  booktitle = {Frontiers in Neurology},
  year = {2023},
  doi = {10.3389/fneur.2023.1152168},
}
Figure